Peterson Katharine 4
4 · Acrivon Therapeutics, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Peterson Katharine
Chief Accounting Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-03-01+31,900→ 31,900 totalExercise: $5.31Exp: 2035-02-28→ Common Stock (31,900 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.